Genentech Reports Sales Growth; Remains Hopeful About Avastin Approval For Breast Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
While its pipeline largely consists of line extensions, firm touts 15 novel compounds added during 2006-2007.